Title |
Allergen-specific oral immunotherapy for peanut allergy
|
---|---|
Published in |
Cochrane database of systematic reviews, September 2012
|
DOI | 10.1002/14651858.cd009014.pub2 |
Pubmed ID | |
Authors |
Ulugbek Nurmatov, Iris Venderbosch, Graham Devereux, F Estelle R Simons, Aziz Sheikh |
Abstract |
Peanut allergy is one of the most common forms of food allergy encountered in clinical practice. In most cases, it does not spontaneously resolve; furthermore, it is frequently implicated in acute life-threatening reactions. The current management of peanut allergy centres on meticulous avoidance of peanuts and peanut-containing foods. Allergen-specific oral immunotherapy (OIT) for peanut allergy aims to induce desensitisation and then tolerance to peanut, and has the potential to revolutionise the management of peanut allergy. However, at present there is still considerable uncertainty about the effectiveness and safety of this approach. |
Twitter Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 8% |
Kyrgyzstan | 1 | 8% |
Netherlands | 1 | 8% |
France | 1 | 8% |
Australia | 1 | 8% |
Unknown | 7 | 58% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 11 | 92% |
Practitioners (doctors, other healthcare professionals) | 1 | 8% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 1 | <1% |
Korea, Republic of | 1 | <1% |
Canada | 1 | <1% |
Slovenia | 1 | <1% |
Spain | 1 | <1% |
Japan | 1 | <1% |
United States | 1 | <1% |
Unknown | 303 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 40 | 13% |
Student > Bachelor | 40 | 13% |
Researcher | 33 | 11% |
Other | 26 | 8% |
Student > Ph. D. Student | 25 | 8% |
Other | 53 | 17% |
Unknown | 93 | 30% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 104 | 34% |
Nursing and Health Professions | 25 | 8% |
Agricultural and Biological Sciences | 20 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 12 | 4% |
Immunology and Microbiology | 8 | 3% |
Other | 35 | 11% |
Unknown | 106 | 34% |